ProQR Therapeutics N.V.

ProQR Therapeutics N.V. shareholders approved several key proposals at the Annual Meeting, including the appointment of KPMG Accountants N.V. as the external auditor for the financial year 2027. Shareholders also approved amendments to the Articles of Association to increase authorized capital, and authorized the Board to issue and acquire ordinary shares. Additionally, the Board determined the new composition of its Audit, Compensation, Nominating and Corporate Governance, and Research and Development Committees, effective June 2, 2026.

ProQR Therapeutics N.V. reported a net loss of 13.4 million for Q1 2026, an increase from 10.1 million in Q1 2025, with revenue decreasing to 2.0 million. The company ended the quarter with 81.1 million in cash and cash equivalents, providing a runway into mid-2027. Operationally, ProQR is on track for AX-0810 target engagement data in Q2 2026, selected biliary atresia as the initial Phase 2 indication, and is advancing multiple other pipeline programs towards clinical trials. The Axiomer platform is also being enhanced with AI-enabled discovery capabilities and a partnership with Ginkgo Bioworks.

ProQR Therapeutics reported its first-quarter 2026 operating and financial results, with a net loss of €13.4 million and cash and cash equivalents of €81.1 million, providing a runway into mid-2027. The company is on track to report AX-0810 target engagement data in Q2 2026 and has selected biliary atresia as the initial Phase 2 indication, with an investigator-initiated trial in China targeting H1 2027 data. ProQR also announced pipeline expansion with AX-0811 and AX-0422 advancing toward the clinic, and continued development of its Axiomer platform, including an AI partnership with Ginkgo Bioworks.

ProQR Therapeutics N.V. announced its Annual General Meeting (AGM) of Shareholders will be held on June 2, 2026, in Amsterdam. The agenda includes the adoption of 2025 annual accounts, the appointment of Dr. Lykke Hinsch Gylvin as a new non-executive board member, and the retirement of Dinko Valerio and Alison Lawton. Shareholders will also vote on increasing the authorized share capital to 270,000,000 for both ordinary and preferred shares and appointing KPMG as the auditor for 2027.

ProQR Therapeutics N.V. announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, to its Board of Directors. Dr. Hinsch Gylvin, currently Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, brings over 20 years of global leadership experience in drug development across various therapeutic areas. Her extensive expertise is expected to complement the Board and support ProQR's pipeline advancement and strategic growth. The nomination awaits shareholder approval at the company's upcoming Annual General Meeting.